Inveready and Caja Navarra invest in Neurotec Pharma
Inveready Seed Capital and Caja Navarra have acquired a 34% stake in pharmaceutical firm Neurotec Pharma.
The remaining equity is held by Neurotec's founders and management team, including Marco Pugliese, Nicole Mahy and Manuel Rodríguez Allue, who control 60% of the business, as well as other business angels.
The capital increase, and agreement with biotech firm Advancell - established in December 2010 - and other investments received by Neurotec represents a total investment of €3.3m, which will enable the firm to finance a clinical trial of multiple sclerosis drug.
More on Southern Europe
PE purchases stall in Italy as buyers lose faith – PE Forum Italy
PE players are hoping that valuation expectations will align in 2H 2023, easing dealmaking backlog
Fondo Agroalimentare Italiano invests in Urbis Food
Deal marks the fund’s full deployment with more than EUR 50m invested across nine transactions
Intesa Sanpaolo investment banking head exits for BNP Paribas
Marco Lattuada previously oversaw activities including M&A and debt capital markets at the Italian firm
William Blair launches Madrid office, adds investment banking practice in Zurich
Álvaro Hernández to lead new Spanish branch; healthcare will be first focus of Swiss expansion
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds